Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp. has reported substantial progress with its MDNA11 immunotherapy, showcasing a 29% response rate in patients resistant to other treatments and a strengthened financial position due to a $20 million investment from RA Capital. The investment extends the company’s operational runway into mid-2026, and with the European Medicines Agency’s approval, the ABILITY-1 study will expand into EU cancer centers. Promising results from MDNA11’s trials, including its safety profile and effectiveness in treating advanced cancers, will be presented in the second half of 2024.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
